DuoNeb has been a subject of a recent Medicare and U.S. Food and Drug Administration (FDA) controversy. FDA has moved for the regulation of generic competition for commercial products. Medicare has moved to limit the reimbursement of commercial products. Dispute resolution will have an economic impact on leading respiratory service providers, as well as patients.
National Asthma Education and Prevention Program Expert Panel 3. Expert panel report 3: guidelines for the diagnosis and management of asthma. Bethesda (MD): National Institutes of Health. National Heart, Lung, and Blood Institute; 2007 Aug. NIH Publication No. 07-4051.